Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon(Medical College of Wisconsin), Bruce Strober(UConn Health), Mark Lebwohl(Icahn School of Medicine at Mount Sinai), Matthias Augustin(Universität Hamburg), Andrew Blauvelt(Oregon Medical Research Center), Yves Poulin(Centre de Recherche Dermatologique du Québec Métropolitain), Kim Papp(Probity Medical Research), Howard Sofen(University of California, Los Angeles), L. Puig(Universitat Autònoma de Barcelona), Peter Foley(University of Melbourne), Mamitaro Ohtsuki(Jichi Medical University), Mary Flack(Boehringer Ingelheim (United States)), Ziqian Geng(AbbVie (United States)), Yihua Gu(AbbVie (United States)), Joaquin Valdes(AbbVie (United States)), Elizabeth H. Thompson(AbbVie (United States)), H. Bachelez(Sorbonne Paris Cité)
Cited by 654
Abstract
Related Papers
No related papers found
Powered by citation graph analysis